阿拓莫兰联合促肝细胞生长素治疗重症肝炎及慢性肝炎重度的体会  

Clinical effect of reduced glutathione with hepatocyte growth-promoting facor in treatment of severe hepatitis and severely chronic hepatitis

作　　者：张袁媛[1] 

机构地区：[1]贵州省遵义医院感染科,563002

出　　处：《重庆医学》2007年第14期1403-1403,1405,共2页Chongqing medicine

摘　　要：目的探讨阿拓莫兰联合促肝细胞生长素对重症肝炎和慢性肝炎重度的临床疗效。方法回顾性病例分析,将108例诊断明确的重症肝炎和慢性肝炎重度病例随机分为治疗组56例,对照组52例,观察两组治疗前后症状和体征及生化指标的改变,统计治疗有效率。结果治疗1个月后治疗组总有效率为94.64%,对照组为80.76%,经统计学处理,差异有统计学意义。结论阿拓莫兰联合促肝细胞生长素对重症肝炎和慢性肝炎重度的临床疗效确切,是综合治疗重症肝炎和慢性肝炎重度的有效组合。Objective To investigate the clinical effect of reduced glutathione（RG）with hepatecyte growth-promoting facor（HGPF）in the treatment of severe hepatitis and severely chronic hepatitis. Methods A total of 108 patients with severe hepatitis and se- verely chronic hepatitis were randomly divided into 2 groups., the treatment group（56 cases）received RG and HGPF for 1 month and the control group（52 cases） received placebo. To investigate the changes in the clinical symptoms and liver function detections be- fore and after the trentment. Results The effective rate of the treatment group and the control group was 94.64 %, 76 % respective- ly. There was statistical difference between the two groups. Conclusion RG with HGPF is an effective combination for the treat- ment of severe hepatitis and severely chronic hepatitis.

关 键 词：重症肝炎 慢性肝炎重度 促肝细胞生长素 阿拓莫兰 

分 类 号：R575.1[医药卫生—消化系统]